RPT

Bain Capital Real Estate and 11North Partners Form Joint Venture to Invest in Open-Air Retail Centers

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Retail, Other Retail, Commercial Building & Real Estate, Finance, Construction & Property, Asset Management, Burger King, Prevalence, Kimco Realty, Partnership, D2C, History, Great, RPT Realty, RPT

Bain Capital Real Estate (“Bain Capital”) and 11North Partners (“11North”), a retail focused investment platform, today announced the formation of a strategic partnership to acquire and operate open-air retail centers throughout the U.S. and Canada.

Key Points: 
  • Bain Capital Real Estate (“Bain Capital”) and 11North Partners (“11North”), a retail focused investment platform, today announced the formation of a strategic partnership to acquire and operate open-air retail centers throughout the U.S. and Canada.
  • 11North was founded by CEO Brian Harper, a 25-year real estate industry veteran with significant retail experience.
  • “Today, open-air retail centers benefit from a confluence of tailwinds and strong real estate fundamentals that create an attractive risk-return opportunity,” said Mr. Harper.
  • We believe there are clear, emerging thematics that support the winning brands, retailers, and commercial real estate of tomorrow.

As Autism in New Jersey Reaches 3rd Highest Rates in Nation, Inspira Health Fills Critical Gap in Providing Diagnoses and Resources for Families

Retrieved on: 
Monday, April 1, 2024
Men, Health, Consumer, Other Philanthropy, Philanthropy, Practice Management, Mental Health, Teens, Parenting, Managed Care, Children, General Health, Women, Nursing, Diagnosis, Assembly, LCSW, Case management, Patient, Mental health, Gold, Research, Child, Credit, CDC, Fracture, RPT, Multimedia, Spectrum, ADC, Family, Parent, State, ASD, Autism spectrum, Vaccine

Inspira Health is proud to announce the opening of its new Autism Diagnostic Center (ADC) to address a critical need in Southern New Jersey.

Key Points: 
  • Inspira Health is proud to announce the opening of its new Autism Diagnostic Center (ADC) to address a critical need in Southern New Jersey.
  • The ADC is designed to offer early testing, diagnosis, and comprehensive resources to children and adults with Autism Spectrum Disorder (ASD).
  • However, other than the newly established diagnostic center, few options and availability exist in South Jersey.
  • Inspira Health’s ADC represents a pivotal step towards nurturing the wellbeing of children with ASD and their families.

Kimco Realty® Announces First Quarter Transaction Activity Highlighted by the Sale of Ten Former RPT Properties for $248 Million

Retrieved on: 
Wednesday, March 27, 2024
Architecture, Professional Services, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Data Analytics, Other Professional Services, Urban Planning, Building Systems, REIT, Finance, Kimco Realty, RPT, Investment, RPT Realty, Sale, Growth, Reinsurance

Kimco Realty® (NYSE: KIM) today announced the disposition of ten former RPT Realty (RPT) properties for an aggregate price of $248 million.

Key Points: 
  • Kimco Realty® (NYSE: KIM) today announced the disposition of ten former RPT Realty (RPT) properties for an aggregate price of $248 million.
  • As part of these sales, Kimco invested approximately $67 million under its Structured Investment program on seven of the properties and expects to earn a 10% blended return on these investments.
  • With these sales, the company has achieved its 2024 disposition target for former RPT properties.
  • “We are very pleased to have completed, ahead of schedule, the sales of the former RPT properties we identified in our underwriting.

Odne announces closing of USD 5.5 million USD Series A1 Financing Round to fund the US market launch

Retrieved on: 
Wednesday, March 13, 2024
Dentistry, LIE, Patient, Endodontics, AAE, Workflow, CHF, RPT, DIA, USD, FDA, Marketing

DUBENDORF, Switzerland , March 13, 2024 /PRNewswire/ -- Odne Ltd, a Swiss dental start-up company and upcoming innovator in endodontic treatments, is pleased to announce the closing of its Series A1 Financing Round raising USD 5.5 million (CHF 4.8 million) to fund the upcoming US market launch.

Key Points: 
  • DUBENDORF, Switzerland , March 13, 2024 /PRNewswire/ -- Odne Ltd, a Swiss dental start-up company and upcoming innovator in endodontic treatments, is pleased to announce the closing of its Series A1 Financing Round raising USD 5.5 million (CHF 4.8 million) to fund the upcoming US market launch.
  • The Odne RPT workflow introduces three new medical devices enabling minimal invasive root canal cleaning and light-cured obturation.
  • "With over 15 million root canal treatments per year, the US is the biggest market worldwide and our number one focus.
  • After receiving FDA clearance for Odne™Cure and Odne™Fill in 2023 the series A1 financing fuels Odne`s US market launch to the endodontic community.

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

Retrieved on: 
Monday, February 26, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Acquisition, BMY, Covington & Burling, Growth, RPT, Bristol Myers Squibb, Cooley LLP, Patient, SSTR2, BofA Securities, Tax, Eastern Time Zone, LLP, IND, Centerview Partners, Pharmaceutical industry

Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB).
  • With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb.
  • “We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.
  • BofA Securities, Inc., is serving as financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.

Kimco Realty® Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 8, 2024
REIT, Retail, Commercial Building & Real Estate, Supermarket, Construction & Property, Security (finance), Class, Growth, Table, GAAP, FFO, Bed Bath & Beyond, N class, Operation, Kimco Realty, RPT Realty, FMV, Investment, Bed, Acquisition, NOI, ACI, Sale, RPT, Share repurchase

Kimco Realty® (NYSE: KIM), North America’s largest publicly listed owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today reported results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Kimco Realty® (NYSE: KIM), North America’s largest publicly listed owner and operator of open-air, grocery-anchored shopping centers and a growing portfolio of mixed-use assets, today reported results for the fourth quarter and full year ended December 31, 2023.
  • “We ended the year with strong results, including leasing an impressive 2.7 million square feet, and achieving positive net absorption and double-digit leasing spreads for the quarter,” said Kimco CEO Conor Flynn.
  • FFO was $239.4 million, or $0.39 per diluted share, compared to $234.9 million, or $0.38 per diluted share, for the fourth quarter of 2022.
  • FFO for the fourth quarter of 2023 included $1.0 million of merger-related charges.

Alaska Energy Metals Provides Corporate Update

Retrieved on: 
Tuesday, January 30, 2024
Copper, National instrument, Resource, Nickel, AEMC, Consultant, Gold standard, OTCQB, News, Marketing, Database, Metal, Platinum, Gold, Data, Palladium, Iron, RPT, Cobalt

VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to provide a corporate update that highlights the accomplishments made since inception in April 2023 and looks ahead to 2024 plans.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Alaska Energy Metals Corporation (TSX-V: AEMC, OTCQB: AKEMF) (“AEMC” or the “Company”) is pleased to provide a corporate update that highlights the accomplishments made since inception in April 2023 and looks ahead to 2024 plans.
  • Alaska Energy Metals Corporation President & CEO Gregory Beischer commented: “I am very proud of what we have accomplished in just 10 months.
  • Last year, we also purchased a company that owns a Quebec nickel project, which came with $2.8 million in cash.
  • After deportment studies are complete, the samples will be subjected to bench-scale flotation testing to determine recovery rates for the metals.

ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program

Retrieved on: 
Tuesday, January 30, 2024
Isotope, ITM, RPT, DMF, Food, Cancer, Patient, Radiopharmaceutical, FDA

GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.

Key Points: 
  • GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical stage biotechnology company developing differentiated and highly targeted radiopharmaceuticals, today announced the signature of a global master clinical supply agreement to support the development of Alpha-9’s Radiopharmaceutical Therapy (RPT) pipeline candidates for the treatment of cancer.
  • Under the terms of the agreement, ITM will supply its medical radioisotope, non-carrier-added Lutetium-177 (n.c.a.
  • 177Lu for the clinical development of Alpha-9 radiopharmaceutical candidates comprising n.c.a.
  • ITM holds a U.S. Drug Master File (DMF) with the Food and Drug Administration (FDA) for n.c.a.

Rapsodo Partners with Titleist to Further Enhance the Premium Member Experience for the Rapsodo MLM2PRO

Retrieved on: 
Tuesday, January 23, 2024
RPT, Golf, Partnership, RCT, Athlete, Pro, MLM, Golf Ball, Sports equipment

Titleist and Rapsodo have partnered to apply the RPT pattern to the #1 ball in golf.

Key Points: 
  • Titleist and Rapsodo have partnered to apply the RPT pattern to the #1 ball in golf.
  • Pro V1 and Pro V1x with RPT will enable MLM2PRO™ to measure spin rate and spin axis.
  • In order to gain access to the spin measurements, users must have a Rapsodo MLM2PRO™ Premium Membership account ($199 annually, included in initial purchase).
  • “The Pro V1 performance golfers trust on the course is now accurately measured wherever you choose to play with your Rapsodo MLM2PRO.

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Retrieved on: 
Friday, January 5, 2024
Molecular imaging, Associate, Perspective, PSMA, Workflow, Research, FRSC, PET, Tissue, Prostate cancer, Mouse, MD, Doctor of Philosophy, Health, Education, Radiology, Therapy, RPT, Mayo Clinic, Prostate, Neoplasm, Kidney, Patient, CATX, Radiation, Medical imaging

SEATTLE, Jan. 05, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), announced today that it has entered into a patent license agreement with Mayo Clinic for the rights to the PSMA Alpha-PET DoubLET platform technology for the treatment of PSMA-expressing cancers, with an initial focus on prostate.

Key Points: 
  • The PSMA Alpha-PET DoubLET platform technology represents a potential leap forward in the field of prostate cancer diagnostics and treatment.
  • This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 (64Cu) for imaging and alpha-particle targeted RPT using lead-212 (212Pb).
  • “This innovative approach developed by Mayo Clinic allows for more precise and personalized treatment plans,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.